Kuraeiad Saruda, Kotepui Kwuntida Uthaisar, Mahittikorn Aongart, Anabire Nsoh Godwin, Masangkay Frederick Ramirez, Wilairatana Polrat, Wangdi Kinley, Kotepui Manas
Medical Technology, School of Allied Health Sciences, Walailak University, Tha Sala, Nakhon Si Thammarat 80160, Thailand.
Center of Excellence in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat 80160, Thailand.
Medicina (Kaunas). 2025 Apr 6;61(4):676. doi: 10.3390/medicina61040676.
: Macrophage inflammatory protein-1α (MIP-1α) and MIP-1β act as signaling molecules that recruit immune cells to sites of infection and inflammation. This study aimed to synthesize evidence on blood levels of MIP-1α and MIP-1β in -infected individuals and to determine whether these levels differ between severe and uncomplicated malaria cases. : The study protocol was registered in PROSPERO (CRD42024595818). Comprehensive literature searches were conducted in six databases (EMBASE, MEDLINE, Ovid, Scopus, ProQuest, and PubMed) to identify studies reporting blood levels of MIP-1α and MIP-1β in infections and clinical malaria. A narrative synthesis was used to describe variations in MIP-1α and MIP-1β levels between malaria patients and controls and between severe and non-severe malaria cases. Meta-analysis was used to aggregate quantitative data utilizing a random-effects model. : A total of 1638 records were identified, with 20 studies meeting the inclusion criteria. Most studies reported significantly higher MIP-1α and MIP-1β levels in malaria patients compared to non-malarial controls. The meta-analysis showed a significant elevation in MIP-1α levels in malaria patients ( = 352) compared to uninfected individuals ( = 274) ( = 0.0112, random effects model, standardized mean difference [SMD]: 1.69, 95% confidence interval [CI]: 0.38 to 3.00, : 96.0%, five studies, 626 individuals). The meta-analysis showed no difference in MIP-1α levels between severe malaria cases ( = 203) and uncomplicated cases ( = 106) ( = 0.51, SMD: -0.48, 95% CI: -1.93 to 0.96, : 97.3%, three studies, 309 individuals). : This study suggests that while MIP-1α and MIP-1β levels are elevated in malaria patients compared to uninfected individuals, these chemokines show a limited ability to differentiate between severe and uncomplicated malaria or predict severe outcomes. Further research is needed to clarify their role in malaria pathogenesis and explore potential clinical applications.
巨噬细胞炎性蛋白-1α(MIP-1α)和MIP-1β作为信号分子,可将免疫细胞招募到感染和炎症部位。本研究旨在综合分析感染个体血液中MIP-1α和MIP-1β水平的证据,并确定这些水平在重症和非重症疟疾病例之间是否存在差异。:该研究方案已在国际前瞻性系统评价注册库(PROSPERO,注册号:CRD42024595818)登记。在六个数据库(EMBASE、MEDLINE、Ovid、Scopus、ProQuest和PubMed)中进行了全面的文献检索,以识别报告感染和临床疟疾中MIP-1α和MIP-1β血液水平的研究。采用叙述性综合分析来描述疟疾病例与对照之间以及重症和非重症疟疾病例之间MIP-1α和MIP-1β水平的差异。采用随机效应模型进行荟萃分析以汇总定量数据。:共识别出1638条记录,其中20项研究符合纳入标准。大多数研究报告称,与非疟疾对照相比,疟疾病例中MIP-1α和MIP-1β水平显著更高。荟萃分析显示,与未感染个体(=274)相比,疟疾病例中MIP-1α水平显著升高(=352)(=0.0112,随机效应模型,标准化均数差[SMD]:1.69,95%置信区间[CI]:0.38至3.00,:96.0%,五项研究,626名个体)。荟萃分析显示,重症疟疾病例(=203)和非重症病例(=106)之间的MIP-1α水平无差异(=0.51,SMD:-0.48,95%CI:-1.93至0.96,:97.3%,三项研究,309名个体)。:本研究表明,虽然与未感染个体相比,疟疾病例中MIP-1α和MIP-1β水平升高,但这些趋化因子区分重症和非重症疟疾或预测严重结局的能力有限。需要进一步研究以阐明它们在疟疾发病机制中的作用,并探索潜在的临床应用。